Merck KGaA Gets Conditional Approval To Market Ezmekly Drug in EU

By Cristina Gallardo

Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval from the European Commission.

The pharmaceutical company said Friday that the European Union's executive had granted a conditional marketing authorization for the drug.

Ezmekly tackles a disorder known as neurofibromatosis type 1 that affects about three in 10,000 people in the EU, or an estimated 135,000 people, and can evolve into a fatal disease, the company said.

The approval was issued to Merck's SpringWorks Therapeutics company, based on the results of an ongoing trial that enrolled 114 patients aged 2 or older, Merck said.

Write to Cristina Gallardo at [e-mail]

(END) Dow Jones Newswires

07-18-25 1247ET